GlaxoSmithKline, Merck KGaA officially call it quits on $4B partnership for flailing cancer drug – Endpoints News
GlaxoSmithKline, Merck KGaA officially call it quits on $4B partnership for flailing cancer drug Endpoints NewsMerck to buy Acceleron for about $11.5 billion in rare-disease drugs push CNBCMerck to acquire Acceleron Pharma in $11.5 billion…
